Monica E. Loghin, M. D.

Peer-Reviewed Articles

1. Yeboa, DN, Whitfield, BT, Lin, R, Ejezie, CL, Swanson, T, Beckham, TH, Wang, C, De, BS, Perni, S, Tom, MC, Li, J, McGovern, SL, Harrison, R, Majd, NK, Puduvalli, VK, Aaroe, AE, Loghin, ME, O'Brien, BJ, Patel, AD, Patel, C, Wefel, JS, Taslicay, CA, Gule-Monroe, MK, Paulino, AC, McAleer, MF, Grosshans, DR, Ghia, AJ, Jiang, W, Chung, C, Maor, MM, Yang, CH, Gubbiotti, M, Kamiya Matsuoka, C, Ballester, L, Weathers, S, Huse, J. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses. Journal of neuro-oncology 176(1), 2026. e-Pub 2026. PMID: 41191157.
2. Weathers, S, Li, X, Zhu, H, Damania, A, Knafl, M, McKinley, BA, Lin, Y, Harrison, R, Majd, NK, O’Brien, BJ, Penas-Prado, M, Loghin, ME, Kamiya-Matsuoka, C, Yung, WA, Solis Soto, LM, Maru, DM, Wistuba, II, Parra Cuentas, ER, Hernandez, S, Futreal, A, Wargo, J, Schulze, K, Darbonne, WC, Ajami, NJ, Woodman, SE, de Groot, JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40289138.
3. Faraj, CA, McCutcheon, IE, Gubbiotti, M, Perni, S, Gule-Monroe, MK, Akdemir, KC, Clark, VE, Bander, ED, Loghin, ME, Prabhu, SS, Lang Jr, FF, Weinberg, J. Extra-central nervous system metastasis from high-grade glioma. Journal of neuro-oncology 173(1):193-204, 2025. e-Pub 2025. PMID: 40055259.
4. Lam, K, Nasr, L, Andersen, C, Marqueen, KE, Li, J, Wang, C, Beckham, TH, Majd, NK, Aaroe, AE, Loghin, ME, O'Brien, BJ, McGovern, SL. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors. Advances in Radiation Oncology 10(2), 2025. e-Pub 2025. PMID: 39866593.
5. Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O'Brien BJ, Majd NK, Loghin ME, Patel CB, Weathers SP, Puduvalli VK, Kamiya-Matsuoka C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study. Neurooncol Pract 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
6. Simbaqueba C, Aaroe A, Rubio D, Loghin ME, Treiber J, Ballester L, Fuller G, Gopakumar S, Kim B, Suarez-Almazor M. Leptomeningeal Immunoglobulin G4–Related Disease: A Case Report. AIM Clinical Cases 2(e230907), 2023. e-Pub 2023.
7. Robertson IJ, Gregory TA, Loghin ME. Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Annals of Case Reports(8):1331, 2023. e-Pub 2023.
8. Robertson IJ, Gregory TA, Loghin ME. Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Ann Case Report 8(3), 2023. e-Pub 2023.
9. Simbaqueba Clavijo, CA, Aaroe, AE, Rubio, D, Loghin, ME, Treiber, J, Ballester, L, Fuller, GN, Gopakumar, S, Kim, BY, Suarez-Almazor, M. Leptomeningeal Immunoglobulin G4–Related Disease. Annals of Internal Medicine Clinical Cases 2(12), 2023. e-Pub 2023.
10. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
11. Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv 4(1):vdac129, 2022. e-Pub 2022. PMID: 36128585.
12. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. e-Pub 2020. PMID: 31755915.

Review Articles

1. Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15:1447021, 2024. e-Pub 2024. PMID: 39247203.

Other Articles

1. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.
2. Robertson IJ, Gregory TA, Loghin ME Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Annals of Case Reports, 2023.

Abstracts

1. Lam, K, Nasr, L, Andersen, C, Marqueen, K, Li, J, Wang, C, Majd, N, Aaroe, AE, Loghin ME, McGovern, S, O'Brien, BJ. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis from Solid Tumors. 29th Annual Meeting of the Society for Neuro-Oncology (SNO) 26(Suppl_8):viii74-viii75, 2024. e-Pub 2024.
2. Kamiya Matsuoka, C, Weathers, SP, Yung, A, Loghin ME, Majd, N, Brown, D, Langlands, J, Schwartz, R, Knight, S, Puduvalli, VK, de Groot, JF, O'Brien, BJ. Assessment of molecular alterations in newly diagnosed GBM MGMT-unmethylated patients treated with VAL-083. 29th Meeting of the Society for Neuro-Oncology (SNO) 26(Suppl_8):viii114, 2024. e-Pub 2024.
3. Weathers S, Kamiya Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova, Aaroe A, Patel C, Loghin M, O'Brien B, Yung WKA, Puduvalli VK, de Groot J. Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma. Neuro-Oncology 25(Suppl_5):v67, 2023. e-Pub 2023.
4. Kamiya Matsuoka C, Weathers S, Yung A, Loghin M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, de Groot J, Puduvalli V, O'Brien B. Evaluation of post-progression treatments after VAL-083 in recurrent and newly diagnosed GBM MGMT unmethylated patients. Neuro-Oncology 25(Suppl_5):v95-v96, 2023. e-Pub 2023.
5. Majd N, Yeboa N, Weathers S, Robichaux C, Al Ansari H, Gachimova E, Loghin M, Kamiya Matsuoka C, O"Brien B, Aaroe A, Patel C, Yung A, Puduvalli V, de Groot J. Phase I clinical trial of peposertib plus radiation in newly diagnosed MGMT-unmethylated glioblastoma. Neuro-Oncology 25(Suppl_5):v84, 2023. e-Pub 2023.
6. Gottiparthy A, Orda-Nguyen L, Morrow E, Loghin ME. Outcomes of Patients with Neoplastic Meningitis Undergoing Ventriculoperitoneal Shunting and Intrathecal Chemotherapy. A single institution retrospective review. Poster Presentation, 2023 Annual Meeting of the American Academy of Neurology, 2023. e-Pub 2023.
7. Gregory T, Loghin M. Case report: extended remission of HER2-positive breast carcinoma with brain metastases and leptomeningeal disease following intrathecal and systemic trastuzumab. Neuro-Oncology 24(Suppl_7):vii198, 2022. e-Pub 2022.
8. Amer A, Darbandi AD, Wang EB, Ciavarra BN, Lano KR, Krayyem A, Alhasan HR, Fuller GR, Ferguson SD, Loghin ME, Li J, McGovern SL, Johnson JM. Clinical and pathologic characteristics of long-term glioblastoma survivors. 2022 ASCO Annual Meeting 40(Number 16_Suppl), 2022. e-Pub 2022.
9. Weathers SS, Zhu H, Knafl M, Damania A, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin ME, Penas-Prado M, Majd N, Yung WKA, O'Brien BJ, Wistuba II, Futreal A, Wargo JA, Ajami NJ, Woodman SE, de Groot JF. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. 2022 ASCO Annual Meeting 40(Number 16_Suppl), 2022. e-Pub 2022.
10. O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, An S, Lopez L, de Groot J. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 23(Suppl_6):vi65, 2021. e-Pub 2021.
11. Weathers SP, Knafl M, Parra E, Hernandez S, Solis L, Sanchez Espiridion B, Wistuba I, Futreal A, Maru D, Kamya-Matsuoka C, Harrison R, Joseph V, Yun C, Darbonne W, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, Woodman S, de Groot J. Biomarker Immune Correlates in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Neuro-Oncology 23(Suppl_6):vi49, 2021. e-Pub 2021.
12. Aaroe AA, Alfaro-Munoa KD, Bornstein C, Kell T, Camp S, Chen M, Woodman K, Tummala S, Kleiman A, de Groot JF, Loghin ME. A Retrospective Single-Center Experience with Nonbacterial Thrombotic Endocarditis and Stroke - Outcomes, Anticoagulation Strategies, and Incorporation of Next-Generation Sequencing Data. Neuro-Oncology 22((suppl 2)):ii127, 2020. e-Pub 2020.
13. Youssef MN, Pham LC, Demirhan M, Harrison RA, Loghin ME, Johnson JK, Alfaro-Munoz KD, Bhat KP, Yeboa D, Prabhu SS, Raza S, de gRoot JF, Demonte F, Kamiya-Matsuoka C. Long-Term Use of Everolimus plus Octreotide for Recurrent Intracranial or Spinal Meningioma: A Single Institution Experience. Neuro-Oncology 22((suppl 2)):ii55, 2020. e-Pub 2020.
14. O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot J. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 22((suppl 2)):ii59, 2020. e-Pub 2020.
15. Weathers SP, Kamiya-Matsuoka C, Harrison R, Liu D, Sanqui, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, de Groot J. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 22((suppl 2)):ii35, 2020. e-Pub 2020.
16. Aaroe A, Team D, Harrison R, Majd N, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, de Groot J, Woodman K. A Snapshot of the Impact of COVID-19 on Patients with Nervous System Tumors. Neuro-Oncology 22((suppl 2)):ii27, 2020. e-Pub 2020.
17. Aaroe AA, Dono A, Youssef M, Alfaro-Munoz K, Weathers S, O’Brien BJ, Majd N, Harrison RA, Loghin ME, Soomro Z, Williford G, Fuller G, Yung WK, Yeboa D, Esquenazi, Ballester LY, de Groot JF, Kamiya Matsuoka C. A Retrospective Study of Treatment Strategies and Outcomes in WHO Grade II and III Isocitrate Dehydrogenase (IDH) Wild-Type Astrocytoma. Neuro-Oncology 22((suppl 2)):ii164-ii165, 2020. e-Pub 2020.
18. Weathers S, Kamiya Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd N, Yung WK, O’Brian BJ, de Groot JF. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Journal of Clinical Oncology 38(suppl_15), 2020. e-Pub 2020.
19. O'Brien B, Penas-Prado M, Kamiya C, Weathers SP, Yung WK, Loghin M, Harrison RA, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot JF. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro-Oncology 21(suppl_6):vi14-vi15, 2019. e-Pub 2019.
20. Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot J, O'Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Neuro-Oncology Advances 1(suppl_1):i8, 2019. e-Pub 2019.
21. Kamiya Matsuoka C, Metrus N, Weathers S, Ross J, Shaw KR, Penas-prado M, Loghin ME, Alfaro-Munoz K, O'Brien BJ, Harrison R, Sadighi Z, Majd N, Yung WK, Meric-Bernstam F, Hambardzumyan D, de Groot J. Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline Mutations?. Annals of Oncology 30(suppl_5):v143-v158, 2019. e-Pub 2019.
22. Metrus N, Daher A, Harrison R, Majd N, Maraka S, Nam J, Trevino C, Weathers S, O'Brien B, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WK, de Groot J, Penas-Prado M. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Neuro-Oncology 20(suppl_6):vi141, 2018. e-Pub 2018.
23. de Groot J, Penas-Prado M, Mandel J, O'Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse J, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger A. Window-of-Opportunity Clinical Trial of Pembrolizumab in Recurrent Glioblastoma Patients. Neuro-Oncology 20(suppl_6):vi2, 2018. e-Pub 2018.
24. Penas-Prado M, Weathers S, Zhou S, Kamiya-Matsuoka C, O'Brien B, Loghin M, Harrison R, Pei B, Ictech S, Hunter K, Yung WK, de Groot J, Shpall EJ, Heimberger A, Rezvani K. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Neuro-Oncology 20(suppl_6):vi2–vi3, 2018. e-Pub 2018.
25. Weathers S, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O'Brien B, Harrison R, Yung WK, Penas-Prado M, de Groot J. Safety Run-In Results for a Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 20(suppl_6):vi9–vi10, 2018. e-Pub 2018.
26. Kamiya Matsuoka C, Metrus NR, Shaw KR, Penas-Prado M, Weathers, SS, Loghin ME, Alfaro-Munoz K, Yuan Y, O'Brien BJ, Harrison, RA, Yung, WK, Meric-Bernstam F, Groot D, JF. The Natural Course of Hypermutator Gliomas. Journal of Clinical Oncology 36(suppl), 2018. e-Pub 2018.
27. Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont I, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de GRoot JF, Yung WK, Penas-Prado M. Phase I Factorial Study of Temozolomide Plus Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy for Newly Diagnosed Glioblastoma. Journal of Clinical Oncology 36(suppl), 2018. e-Pub 2018.
28. Kamiya-Matsuoka C, Shaw K, Loghin M, Penas-Prado M, O'Brien B, Weathers S, Alfaro-Munoz K, Yung WK, de Groot J. The Natural Course of Hypermutator Gliomas. Neuro-Oncology 19(suppl_6):vi179, 2017. e-Pub 2017.
29. Nam, J, Harrison RA, Weathers SP, Pillainayagam C, de Groot JF, Kamiya-Matsuoka C, Loghin ME, Penas-Prado M, Yung WK, Li J, Ferguson SD, O'Brien BJ. Association of Clinical Phenotype and Treatment History with Survival in Adult Brainstem Glioblastoma. Journal of Clinical Oncology 35(suppl), 2017. e-Pub 2017.
30. Hasan T, Maraka S, Leeds N, Loghin ME. A Rare Case of Primary Angitis of the Central Nervous System (PACNS) Associated with Metastatic Prostate Cancer. Proceedings In: Annual American Academy of Neurology Meeting, 2017, 2017. e-Pub 2017.
31. Gatson N, Kamiya Matsuoka C, Rodriguez-Linares Y, Pillainayagan C, Cachia D, Chi L, Weinberg J, Tremont I, Fuller G, de Groot J, Loghin M. Gliomatosis, To Be or Not To Cerebri: An Evaluation of Host Systemic Immune Factors That Potentially Predispose to Diffuse Infiltrative Glioma Pattern. Neuro-Oncology 18(suppl_6):vi165, 2016. e-Pub 2016.
32. Gatson NT, Kamiya-Matsuoka C, Rodriguez-Linares Y, Pillainayagam CP, Cachia D, Daher AM, Chi TL, Weinberg JS, Tremont-Lukats IW, Fuller GN, de Groot JF, Loghin M. Gliomatosis, to be or not to cerebri?. Proceedings In: Annual American Academy of Neurology meeting, 2016, 2016. e-Pub 2016.
33. Raizer J, Grimm S, Penas-Prado M, Tremont I, Yung A, Avgeropoulos, Walbert T, Loghin M, Gilbert M. A Phase I-II Trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas: Brain Tumor Treatment Collaborative Trial 09-01. Neuro-Oncology 17(suppl_5):v15, 2015. e-Pub 2015.
34. Coecho Barata PM, Kamiya-Matsuoka C, Lee-Kim S, Loghin ME, O'Brien BJ, Tremont I. Outcomes After Hospitalization in Patients with Recurrent Glioblastoma. Journal of Clinical Oncology 33(suppl), 2015. e-Pub 2015.
35. Penas-Prado M, Hess KR, Levin VA, de Groot JF, Colman H, Groves MD, Conrad CA, Loghin ME, Hunter K, Gilbert MR, Yung WK, Puduvalli VK. Phase I Study of Vorinostat Combined with Isotretinoin and Temozolomide in Adults with Recurrent Malignant Gliomas. Journal of Clinical Oncology 33(suppl), 2015. e-Pub 2015.
36. Raizer JJ, Grimm SA, Penas-Prado M, Tremont I, Yung WK, Avgeropoulos NG, Walbert T, Loghin ME, Gilbert MR. A Phase I Trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas: Brain Tumor Treatment Collaborative Trial 09-01. Journal of Clinical Oncology 33(suppl), 2015. e-Pub 2015.
37. Loghin M, Melhem-Bertrandt A, Penas-Prado M, Zaidi T, Katz R. HER2 targeted therapies and leptomeningeal disease. Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO), 2013, San Francisco, CA, November 21 – 24, 2013 15(supplement 3):iii119, 2013. e-Pub 2013.
38. Conrad C, Yung WKA, deGroot J, Gilbert M, Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D. Phase 1 trial of bevacizumab plus TPI 287 in adults with recurrent glioblastoma (GBM). Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, 2013, (SNO) San Francisco, CA, November 21 – 24, 2013 15(supplement 3):iii106, 2013. e-Pub 2013.
39. Case, D, Naughton MJ, Stieber VW, Bayer GK, Bilodeau PA, Moore DF, Falchuk SC, Needles BM, Piephoff J, Edenfield WJ, Giguere JK, Erickson N, Loghin ME, Shaw EG, Rapp SR. Quality of life (QOL) and cognitive status among irradiated brain tumor survivors treated with donepezil or placebo. J Clin Oncol 31, 2013 (suppl; abstr 2051). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013. e-Pub 2013.
40. Abouharb S, Ensor J, Loghin ME, Katz R, Gonzalez-Angulo AM, Esteva FJ, Moulder SL, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: Relationship of outcome and subtype. J Clin Oncol 31, 2013 (suppl; abstr 601 ). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013. e-Pub 2013.
41. Rapp, SR, Case D, Peiffer A, Naughton MJ, Stieber VW, Bayer GK, Bilodeau PA, Moore DF, Falchuk C, Needles BM, Piephoff J, Edenfield WJ, Giguere JK, Erickson N, Loghin ME, Shaw EG. Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors. J Clin Oncol 31, 2013 (suppl; abstr 2006). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013. e-Pub 2013.
42. Raizer JJ, Giglio P, Hu JL, Groves MD, Merrell R, Conrad CA, Phuphanich S, Puduvalli VK, Loghin ME, Paleologos N, Yung WKA, Vaillant BD, Rudnick JD, Chamberlain MC, Vick N, Grimm SA, Tremont-Lukats I, DeGroot JF, Aldape KD, Gilbert MR. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GMB) without MGMT promoter methylation. J Clin Oncol 31, 2013 (suppl; abstr 2019). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013. e-Pub 2013.
43. Penas-Prado M, Groves MD, Mammoser AG, Melguizo I, groot D, JF, Conrad CA, Tremont-Lukats I, Loghin ME, Puduvalli VK, Sulman EP, Hess, KR, Aldape KD, Gilbert MR, Yung, WKA. Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma. J Clin Oncol 31, 2013 (suppl; abstr TPS2106 ). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013. e-Pub 2013.
44. Puduvalli VK, Groves MD, Gilbert MR, Hess KR, Kang S, Ictech S, Conrad CA, Loghin ME, Groot JF, Levin VA, Yung WKA. Lenalidomide and irinotecan in adults with recurrent malignant gliomas: Phase I results of the phase I/II trial. J Clin Oncol 30, 2012 (suppl; abstr 2036). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2012, June 1- June 5, 2012, Chicago, IL, 2012. e-Pub 2012.
45. Gilbert MR, Hess KR, Lagrone L, Groves MD, Levin VA, de Groot JF, Loghin ME, Puduvalli VK, Fisch M, Giglio P, Colman H, Conrad CA, Aldape KD, Yung WK. Factorial Design of Dose-Dense Temozolomide Alone and in Combination with Permutations of Thalidomide (Thal), Isotretinoin (CRA), and/or Celecoxib (Cel) as Post-Chemoradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma (GBM). Journal of Clinical Oncology 30(suppl), 2012. e-Pub 2012.
46. Gilbert MR, Hess KR, Lagrone L, Groves MD, Levin VA, De Groot J, Loghin ME, Puduvalli VK, Fisch M, Giglio P, Colman H, Conrad CA, Aldape KD, Yung WKA. Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). J Clin Oncol 30, 2012 (suppl; abstr 2003). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2012, June 1- June 5, 2012, Chicago, IL, 2012. e-Pub 2012.
47. Zohrevand P, Loghin M. Transient Leukoencephalopathy after Intrathecal Chemotherapy Mimicking Stroke. Neurology. In Proceedings: American Academy of Neurology (AAN) meeting, New Orleans LA 4/24-4/27/2012 78, 2012. e-Pub 2012.
48. Groves MD, DeGroot J, Loghin M, Conrad C, Hess K, Ictech S, Hunter K, Yung WKA. A phase I study of Temozolomide and Intrathecal Liposomal Cytarabine in patients with neuroplastic meningitis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii43, 2011. e-Pub 2011.
49. Colman H, Gilbert M, Yung WKA, Aldape K, deGroot J, Conrad C, Levin V, Groves M, Loghin M, Pelloski C, Puduvalli V. A phase I study of Sorafen1B with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplemement 3):iii61, 2011. e-Pub 2011.
50. Paker AM, Chi L, Kamiya-Matsuoka C, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients. Neurology. In Proceedings: 16 Annual Scientific Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17-20, 2011 78, 2011. e-Pub 2011.
51. Hamilton JD, Levin VA, Hou P, Prabhu S, Loghin ME, Gilbert MR, Bassett RL, Wang J. Advanced MR imaging shows decreased vessel leakiness/edema and may predict complications in Bevacizumab therapy of brain radiation necrosis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii142, 2011. e-Pub 2011.
52. Hamilton JD, Wang J, Levin VA, Hou P, Loghin ME, Gilbert MR, Leeds NE, deGroot, JF, Puduvalli V, Jackson EF, Yung WKA, Kumar AJ. Normalized baseline ADC values predict problems associated with Bevacizumab treatment for glioblastoma multiforme or brain radiation induced necrosis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii137, 2011. e-Pub 2011.
53. Puduvalli VK, Penas-Prado M, Hess KR, Hunter K, Ictech S, Groves MD, Gilbert, Liu V, Conrad CA, degroot J, Loghin ME, Colman H, Levin VA, Yung, WKA. Phase I/II adaptive randomized trial of Vorinostat, Isotretinoin and Carboplatin in adults with recurrent glioblastoma multiforme - results of the phase I arm. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii49, 2011. e-Pub 2011.
54. Paker AM, Chi L, Ruiz MD, Loghin ME. Posterior reversible encephalopathy syndrome in patients with cancer. J Clin Oncol 29: 2011 (suppl; abstr 2561). In Proceedings: 2011 Annual American Society of Clinical Oncology (ASCO), Chicago IL, June 4-7, 2011 29, 2011. e-Pub 2011.
55. Puduvalli VK, Penas-Prado M, Gilbert MR, Groves MD, Hess KR, Levin VA, de Groot J, Colman H, Conrad CA, Loghin ME, Hunter K, Yung WKA. Phase I study of Vorinostat combined with Isotretinoin and Carboplatin in Adults with Recurrent Malignant Gliomas. Neuro-Oncology: In proceedings of the 2010 Annual Meeting of the Society for Neuro-Oncology (SNO), Montreal, Canada, November 18 - November 21, 2010, 2010. e-Pub 2010.
56. Naughton MJ, Case LD, Meyers CA, Loghin ME, Shaw EG, Saphner TJ, Sleckman BG, Giguere JK, Lesser GJ, Rapp SR. Quality of life (QOL) and cognitive performance among irradiated brain cancer patients. Proceedings of the 46th Annual Meeting of the American Society of Clinical Oncology, (ASCO) Chicago, IL, June 4-8, 2010 28(15S, Part I of II):668s, 2010. e-Pub 2010.
57. Rapp SR, Case LD, Loghin ME, Meyers CA, Saphner TJ, Sleckman BG, Stieber VW, Atkins JN, Giguere JK, Shaw EG. Correlation of cognitive symptoms with cognitive performance among brain cancer patients after radiation therapy. Proceedings of the 46th Annual Meeting of the American Society of Clinical Oncology, (ASCO) Chicago, IL, June 4-8, 2010 28(15S, Part I of II):200s, 2010. e-Pub 2010.
58. Fuller GN, Grewal J, Kallio M, Loghin M, Debnam JM, McCutcheon IA. Pleomorphic pineal parenchymal tumor of intermediate differentiation. Proceedings of the 12th Annual Meeting of the Society for Neuro-Oncology, (SNO) Dallas, TX, November 15-18, 2007 PA-40:551, 2007. e-Pub 2007.
59. Loghin M, Groves M. Neoplastic meningitis in unknown primary neoplasms. Journal of Clinical Oncology. In: 2006 ASCO Annual Meeting Proceedings, 2006, Atlanta Georgia 24(18-S), 2006. e-Pub 2006.

Book Chapters

1. Majd NK, Loghin M. Leptomeningeal Disease in Solid Cancers. In: Oncologic Critical Care. Springer, Cham, 2019.
2. Loghin M, Kleiman A. Medication-Induced Neurotoxicity in Critically Ill Cancer Patients. In: Oncologic Critical Care. Springer, Cham, 2019.